Abacus Global Management (NASDAQ:ABL) said on Friday it has authorized a $20 million share repurchase program, underscoring its confidence in the company’s fundamentals and future performance.
The repurchase program, approved by Abacus’s Board of Directors, will be in effect for up to 18 months.
Silver prices continued to make gains on Friday, trading above $36 per ounce, their highest level in more than 13 years.
Prices have increased approximately 24.3% since the start of the year, supported by a persistent supply deficit and increasing demand from both investors and industrial users.
Medicus Pharma (NASDAQ:MDCX) said it has appointed KPMG as its independent registered public accounting firm for the 2025 fiscal year, replacing EisnerAmper following a review process led by the company’s audit committee and approved by its board.
The transition, announced on June 4, comes as the clinical-stage biotech company ramps up its global operations and research programs.
HIVE Digital Technologies (TSX-V:HIVE, NASDAQ:HIVE) announced a 58% increase in peak Bitcoin mining hashrate for May 2025, rising from 6.6 EH/s in April to 10.4 EH/s, as the company continues to scale operations and expand capacity.
The company attributed this growth to the successful energization of HIVE’s 100 MW hydro-powered facility in Paraguay, contributing to its global network powered entirely by hydroelectric energy.
Candel Therapeutics Inc (NASDAQ:CADL) has appointed biotechnology industry veteran Maha Radhakrishnan, M.D., to its board of directors.
Dr Radhakrishnan brings more than two decades of experience in drug development and commercialization across multiple therapeutic areas.
Shares of TNR Gold Corp (TSX-V:TNR, OTC:TRRXF) are set to end the week on a high after the royalty company's stock spiked on Thursday, climbing as much as 33% to an intraday high of $0.08 and continued to add another 13% on Friday.
Trading volume spiked to 3.7 million shares—well above average—as investors responded to growing market interest in the company's strategic review and prized royalty assets.
Shares in ValiRx fell 10% after the biotech firm published its 2024 results, highlighting a continued loss and a warning over its future funding needs.
The drug development micro-cap reported a total loss of £1.92 million for the year, slightly lower than the previous year, and a loss per share of 1.45p.
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) is close to finalising a long-awaited $320 million financing package for its Tulu Kapi gold project in Ethiopia, paving the way for construction to begin and full production by late 2027.
The company said the funding syndicate, which includes two African development banks, contractors and local investors, is now at the final approval stage.
Bango PLC (AIM:BGO, OTCQX:BGOPF) has forecast continued growth in 2025, buoyed by strong early sales of its Digital Vending Machine and improved financing arrangements that give the subscription technology group more room to manage costs.
The Cambridge-based company, which enables telcos and retailers to bundle streaming and other digital services, said it had already signed four new customers in the first quarter of 2025, more than half the total added in the whole of the previous year.
Imugene Ltd earlier this week provided updates on its advancing oncology pipeline following the appointment of Dr John Byon as chief medical officer and activation of the first site in the Phase 2 trial of PD1-Vaxx.
